Abstract
The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.
| Original language | English |
|---|---|
| Pages (from-to) | 47777-47793 |
| Number of pages | 17 |
| Journal | Oncotarget |
| Volume | 7 |
| Issue number | 30 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- Anticancer drug
- Antiviral innate immunity
- Chemokine
- Transcriptome profiling
- Tumor necrosis factor alpha
ASJC Scopus subject areas
- Oncology
Cite this
Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. / Lulli, Daniela; Carbone, Maria Luigia; Pastore, Saveria.
In: Oncotarget, Vol. 7, No. 30, 2016, p. 47777-47793.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin
AU - Lulli, Daniela
AU - Carbone, Maria Luigia
AU - Pastore, Saveria
PY - 2016
Y1 - 2016
N2 - The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.
AB - The Epidermal Growth Factor Receptor (EGFR) is centrally involved in the regulation of key processes of the epithelia, including cell proliferation, survival, differentiation, and also tumorigenesis. Humanized antibodies and small-molecule inhibitors targeting EGFR were developed to disrupt these functions in cancer cells and are currently used in the treatment of diverse metastatic epithelial cancers. By contrast, these drugs possess significant skin-specific toxic effects, comprising the establishment of a persistent inflammatory milieu. So far, the molecular mechanisms underlying these epiphenomena have been investigated rather poorly. Here we showed that keratinocytes respond to anti-EGFR drugs with the development of a type I interferon molecular signature. Upregulation of the transcription factor IRF1 is early implicated in the enhanced expression of interferon-kappa, leading to persistent activation of STAT1 and further amplification of downstream interferoninduced genes, including anti-viral effectors and chemokines. When anti-EGFR drugs are associated to TNF-a, whose expression is enhanced by the drugs themselves, all these molecular events undergo a dramatic enhancement by synergy mechanisms. Finally, high levels of interferon-kappa can be observed in epidermal keratinocytes and also in leukocytes infiltrating the upper dermis of cetuximab-driven skin lesions. Our data suggest that dysregulated activation of type I interferon innate immunity is implicated in the molecular processes triggered by anti-EGFR drugs and leading to persistent skin inflammation.
KW - Anticancer drug
KW - Antiviral innate immunity
KW - Chemokine
KW - Transcriptome profiling
KW - Tumor necrosis factor alpha
UR - http://www.scopus.com/inward/record.url?scp=84982851832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982851832&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.10013
DO - 10.18632/oncotarget.10013
M3 - Article
VL - 7
SP - 47777
EP - 47793
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 30
ER -